Skip to main content
Equibles

ATHE · Alterity Therapeutics Ltd · Metrics

Track ATHE — free

Use ATHE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATHE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.10 -0.22 (-9.31%) At close · Nov 12 Q2 2021 earnings call transcript
Rebalance outlook locked
Market Cap
$40.00M
Shares
19.09M
Volume · Nov 12 71.75K Avg daily vol (3M) 86.25K

ATHE metrics

50 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.10
Market cap
$40.00M

Price action

23 metrics
Price change (1W)
-5.3%
Price change (30D)
-18.9%
Price change (3M)
-53.0%
Price change (6M)
-50.0%
Price change (YTD)
-25.0%
Price change (1Y)
-37.1%
Trailing year
Price change (5Y)
—
52-week high
$5.89
52-week low
$2.08
Change from 52-week high
-60.8%
Change from 52-week low
+11.1%
Annualized volatility
68.7%
Annualized volatility (3M)
79.0%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.2
RSI (14D)
40.1
Price vs SMA 50
-26.4%
Price vs SMA 200
-41.3%
Avg volume (3M)
85,547
Relative volume
0.2
Average dollar volume
$232,050

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.09M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.5
reciprocal yield 67.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2020-12-31

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.36

Growth

11 metrics
Revenue growth YoY
+88.6%
Year over year
Net income growth YoY
+7.5%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-97.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+16.4%
Revenue CAGR (5Y)
+125.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
50.5%
Debt / equity
—
Current ratio
14.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
14.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$25.81M
Total assets
$31.82M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
21
13F filer change QoQ
+6
Institutional ownership
2.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+26.5%
Holder tenure
11.2
Price vs estimated holder cost
+21.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
26 / 100

Insider activity

2 metrics
Net insider buying (90D)
$23,810
Insider-sentiment score
80 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 14 filings 14 filers Visit website Investor relations